Chemed (CHE) is trading lower as the market reacts to updated 2026 expectations for its two core businesses—VITAS hospice and Roto-Rooter plumbing—where management’s outlook suggests a more measured growth profile and tighter margins than some investors were positioned for. The read-through is that near-term earnings power could remain constrained even if top-line trends stay positive. (tipranks.com)

In the outlook framework being circulated by market news feeds, VITAS is still projected to grow revenue and average daily census, but EBITDA margin is framed around roughly 17.5%–18% before the Medicare cap. The same update flags Medicare cap billing forecast around $9.5 million, while Roto-Rooter targets revenue growth with an adjusted EBITDA margin around 22.5%–23%, giving investors clearer (and in some cases lower) profitability benchmarks. (tipranks.com)

For a stock like CHE—often valued on the durability of hospice cash flows and the steadiness of Roto-Rooter margins—any guidance that points to constrained operating leverage can pressure the multiple quickly. Today’s move appears to be driven more by margin sensitivity and the Medicare-cap framing than by an outright collapse in demand, with traders recalibrating expectations for how quickly earnings can re-accelerate. (tipranks.com)

Investors will likely focus on incremental disclosures around VITAS profitability, Medicare-cap exposure, and whether Roto-Rooter can hold the targeted margin range as it pursues growth. Near-term trading could remain headline-driven into the next scheduled catalyst, as the market looks for confirmation that 2026 is a stabilization year rather than the start of a longer margin reset. (tipranks.com)